Sacituzumab govitecan ,Trodelvy ,TROP-2 ,IMMU-132 ,Oncology ADC / Triple-negative breast cancer ADC / Urothelial cancer ADC ,CAS No.1491917-83-9
Trade Name : TrodelvyTarget : TROP-2Molecular Type : ADCSales in 2025 (Millions of USD) : 1014(First three quarters)All detailed product information shall be subject to the issued final COA.Should you need further in-depth documentation for this item, kindly get in touch with us.
Trade Name : Trodelvy
Target : TROP-2
Molecular Type : ADC
Sales in 2025 (Millions of USD) : 1014(First three quarters)
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.
Bevacizumab ,Avastin ,VEGF ,Anti-VEGF monoclonal antibody ,Anti-VEGF monoclonal antibody ,Humanized IgG1 antibody ,Oncology biologic / Anti-angiogenic therapy ,CAS No.216974-75-3
Trade Name : Avastin Target : VEGF Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Vedolizumab ,Entyvio ,MLN0002 ,Anti-integrin biologic ,Humanized IgG1 monoclonal antibody ,IBD therapeutic / Ulcerative colitis biologic / Crohn's disease biologic ,CAS No.943609-66-3
Trade Name : Entyvio Target : N/A Molecular Type : N/A Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Imiglucerase ,Cerezyme ,rGCR ,GBA (β- glucocerebrosid ase) ,Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) ,CAS No.154248-97-2
Trade Name : Cerezyme® Target : GBA (β- glucocerebrosid ase) Molecular Type : Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) Sales in 2025 (Millions of USD) : 1105(estimate) All detailed product information shall be subject to the issued final ...
Luspatercept-aamt ,Reblozyl ,ACE-536 ,Recombinant fusion protein ,Activin receptor trap ,Transforming growth factor-β (TGF- β)superfamily ligands ,Recombinant Fusion Protein
Trade Name : Reblozyl Target : Transforming growth factor-β (TGF- β)superfamily ligands Molecular Type : Recombinant Fusion Protein Sales in 2025 (Millions of USD) : 2000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for ...
